according to the Hazardous Products Regulations



Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	19339-00022	Date of first issue: 10/07/2014

SECTION 1. IDENTIFICATION

Product name	:	Losartan Formulation
Other means of identification	:	No data available

Manufacturer or supplier's details

Company name of supplier	:	Organon & Co.
Address	:	30 Hudson Street, 33nd floor
		Jersey City, New Jersey, U.S.A 07302
Telephone	:	1-551-430-6000
Emergency telephone	:	1-215-631-6999
E-mail address	:	EHSSTEWARD@organon.com
_		

Recommended use of the chemical and restrictions on use

Recommended use	:	Pharmaceutical
Restrictions on use	:	Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accor Acute toxicity (Oral)	dan :	ce with the Hazardous Products Regulations Category 4
Serious eye damage	:	Category 1
Skin sensitization	:	Category 1
Reproductive toxicity	:	Category 1B
Effects on or via lactation		
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)
GHS label elements Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	 H302 Harmful if swallowed. H317 May cause an allergic skin reaction. H318 Causes serious eye damage. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

according to the Hazardous Products Regulations



Losartan Formulation

ersion 1	Revision Date: 09/26/2023	SDS Number: 19339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014
Precautionary Statements :		P202 Do not ha and understood P260 Do not br P263 Avoid cor P264 Wash ski P270 Do not ea P272 Contamir the workplace.	reathe dust. ntact during pregnancy and while nursing. in thoroughly after handling. at, drink or smoke when using this product. nated work clothing should not be allowed out of ntective gloves, protective clothing, eye protection
		unwell. Rinse n P302 + P352 If P305 + P351 + water for sever and easy to do CENTER. P308 + P313 If P333 + P313 If tion.	 P330 IF SWALLOWED: Call a doctor if you feel nouth. F ON SKIN: Wash with plenty of water. P338 + P310 IF IN EYES: Rinse cautiously with al minutes. Remove contact lenses, if present Continue rinsing. Immediately call a POISON F exposed or concerned: Get medical attention. F skin irritation or rash occurs: Get medical atten- Fake off contaminated clothing and wash it before
		Storage: P405 Store loc	ked up.
		Disposal: P501 Dispose disposal plant.	of contents and container to an approved waste
Conta	r hazards act with dust can cause orm explosive dust-air		or drying of the skin. ssing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance /	/ Mixture	:	Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data availa- ble	9004-34-6	>= 30 - < 60 *
Losartan	No data availa- ble	124750-99-8	>= 30 - < 60 *
Starch	Sago starch	9005-25-8	>= 10 - < 30 *

* Actual concentration or concentration range is withheld as a trade secret

according to the Hazardous Products Regulations



Losartan Formulation

Version 5.1	Revision Date: 09/26/2023	SDS Number: 19339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014			
SECTION	SECTION 4. FIRST AID MEASURES					
Gene	ral advice	advice immed	accident or if you feel unwell, seek medical liately. Ins persist or in all cases of doubt seek medical			
lf inha	aled		nove to fresh air.			
In cas	se of skin contact	: In case of cor of water. Remove cont Get medical a Wash clothing	Get medical attention. In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.			
In cas	se of eye contact	: In case of cor for at least 15 If easy to do,	ntact, immediately flush eyes with plenty of water			
lf swa	allowed	: If swallowed, Get medical a Rinse mouth	DO NOT induce vomiting.			
	important symptoms iffects, both acute and ed	 Harmful if swallowed. May cause an allergic skin reaction. Causes serious eye damage. May damage the unborn child. May cause harm to breast-fed children. May cause damage to organs through prolonged or repexposure if swallowed. Contact with dust can cause mechanical irritation or dry the skin. 				
Prote	ction of first-aiders	: First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for exposure exists (see section 8).				
Notes	s to physician		matically and supportively.			

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Chlorine compounds Nitrogen oxides (NOx)

according to the Hazardous Products Regulations



Losartan Formulation

Versi 5.1	on	Revision Date: 09/26/2023		9S Number: 339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014
Specific extinguishing meth- ods Special protective equipment		:	Use extinguishing measures that are appropriate to local cir cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to so. Evacuate area. In the event of fire, wear self-contained breathing apparatus		
1	for fire-f	fighters		Use personal prot	ective equipment.
SEC	TION 6.	ACCIDENTAL RELE	ASI	EMEASURES	
t	tive equ	al precautions, protec- lipment and emer- procedures	:		ective equipment. ing advice (see section 7) and personal ent recommendations (see section 8).
I	Environ	mental precautions	:	Retain and dispos	akage or spillage if safe to do so. e of contaminated wash water. should be advised if significant spillages
-	Methods and materials for containment and cleaning up		:	container for dispo Avoid dispersal of with compressed Dust deposits sho surfaces, as these released into the a Local or national r disposal of this ma employed in the c determine which r Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

SECTION 7. HANDLING AND STORAGE

Technical measures	 Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	 Avoid contact during pregnancy and while nursing. Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed.

according to the Hazardous Products Regulations



Losartan Formulation

Version 5.1	Revision Date: 09/26/2023	SDS Number: 19339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014			
		Keep container Keep away fror Take precaution Do not eat, drin	generation and accumulation. closed when not in use. n heat and sources of ignition. nary measures against static discharges. k or smoke when using this product. event spills, waste and minimize release to the			
Conditions for safe storage		: Keep in properly labeled containers. Store locked up. Keep tightly closed.				
Materials to avoid		: Do not store wi Strong oxidizing	ibstances and mixtures			

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

:

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellulose	9004-34-6	TŴA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respir- able dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Losartan	124750-99-8	TWA	100 µg/m3 (OEB 2)	Internal
Starch	9005-25-8	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respir- able dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m³	ACGIH

Engineering measures

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts,

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

according to the Hazardous Products Regulations



Losartan Formulation

Version 5.1	Revision Date: 09/26/2023	SDS Number: 19339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014			
		If sufficient ventilation.	ventilation is unavailable, use with local exhaust			
Perso	onal protective equip	ment				
Resp	Respiratory protection		local exhaust ventilation is not available or sessment demonstrates exposures outside the ed guidelines, use respiratory protection.			
Filter type Hand protection		: Particulates				
Ma	aterial	: Chemical-re	sistant gloves			
Re	emarks	on the conce time is not d For special a resistance to gloves with	ves to protect hands against chemicals depending entration specific to place of work. Breakthrough etermined for the product. Change gloves often! applications, we recommend clarifying the o chemicals of the aforementioned protective the glove manufacturer. Wash hands before at the end of workday.			
Еуе р	protection	: Wear the fol Chemical re	Wear the following personal protective equipment: Chemical resistant goggles must be worn. If splashes are likely to occur, wear:			
Skin a	Skin and body protection Skin and body protection Skin and body protection Skin and body protection Skin and an assessment of the local potential. Skin contact must be avoided by using impervious clothing (gloves, aprons, boots, etc).					
Hygie	ene measures	: If exposure the eye flushing working place.	to chemical is likely during typical use, provide systems and safety showers close to the			

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	White to light yellow
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available

according to the Hazardous Products Regulations



Losartan Formulation

Versio 5.1	n	Revision Date: 09/26/2023		S Number: 39-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014
E	vapora	ation rate	:	No data available	9
FI	lamma	ability (solid, gas)	:	May form explosi handling or other	ive dust-air mixture during processing, means.
FI	lamma	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available	9
		explosion limit / Lower bility limit	:	No data available	9
V	apor p	pressure	:	No data available	9
R	elative	e vapor density	:	No data available	9
R	elative	e density	:	No data available	9
D	ensity		:	1 g/cm ³	
S	olubilii Wate	ty(ies) er solubility	:	No data available	
	artitior	n coefficient: n-	:	No data available	9
		ition temperature	:	No data available	9
D	ecom	position temperature	:	No data available	9
Vi	íscosit Visc	ty osity, kinematic	:	No data available	
E	xplosi	ve properties	:	Not explosive	
0)xidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.
М	lolecul	lar weight	:	No data available	9
М	1inimu	m ignition energy	:	> 300 mJ	
Pa	article	size	:	No data available	9

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
tions		nandling or other means. Can react with strong oxidizing agents.

according to the Hazardous Products Regulations



Losartan Formulation

rsion	Revision Date: 09/26/2023		OS Number: 339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014				
Condi	tions to avoid	:	Heat, flames Avoid dust fo					
Incom	patible materials	:	Oxidizing age					
	dous decomposition	:	No hazardou	s decomposition products are known.				
products								
	nation on likely rout	es of	exposure					
Inhala Skin o	tion ontact							
Ingest								
Eye co								
Acute	toxicity							
Harmf	ul if swallowed.							
<u>Produ</u>	ict:							
Acute	oral toxicity	:	Acute toxicity Method: Calcu	estimate: 1,502 mg/kg Ilation method				
<u>Comp</u>	onents:							
Cellul	ose:							
Acute	oral toxicity	:	LD50 (Rat): >	5,000 mg/kg				
Acute	inhalation toxicity	:	LC50 (Rat): > Exposure time					
			Test atmosphe					
Acute	dermal toxicity	:	LD50 (Rabbit)	: > 2,000 mg/kg				
Losar	tan:							
Acute	oral toxicity	:	LD50 (Mouse)	: 1,257 - 1,590 mg/kg				
			LDLo (Rat): 20	00 mg/kg				
			LDLo (Mouse)	: 400 mg/kg				
Starcl	ו:							
Acute	oral toxicity	:	LD50 (Rat): >	5,000 mg/kg				
Acute	dermal toxicity	:	LD50 (Rabbit)	: > 2,000 mg/kg				
Skin o	corrosion/irritation							
Not cla	assified based on ava	ailable	information.					
Comn	onents:							

according to the Hazardous Products Regulations

SDS Number:



Date of last issue: 03/20/2023

Losartan Formulation

Revision Date:

Version

rsion	Revision Date: 09/26/2023	SDS Number: 19339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014				
Species Result		: Rabbit : Mild skin irritati					
Serio	us eye damage/eye	irritation					
Cause	es serious eye damag	je.					
<u>Comp</u>	<u>oonents:</u>						
Losai	rtan:						
Speci		: Rabbit					
Resul	t	: Severe irritation	1				
Starc	h:						
Speci	es	: Rabbit					
Resul		: No eye irritation	1				
Resp	iratory or skin sensi	tization					
Skin	sensitization						
May c	ause an allergic skin	reaction.					
Resp	iratory sensitization						
Not cl	assified based on ava	ailable information.					
<u>Com</u>	oonents:						
Losai	rtan:						
Test 7		: Maximization T	est				
Route Speci	es of exposure	: Skin contact : Guinea pig					
•	ssment		vidence of skin sensitization in humans				
Resul		: positive					
Starc	h:						
Test 1	Гуре	: Maximization T	est				
Route	es of exposure	: Skin contact					
Speci Resul		: Guinea pig					
Resul	it i	: negative					
	cell mutagenicity						
	assified based on ava	ailable information.					
Comp	<u>oonents:</u>						
Cellu							
Geno	toxicity in vitro	: Test Type: Bac Result: negativ	terial reverse mutation assay (AMES) e				
		Test Type: In v Result: negativ	itro mammalian cell gene mutation test e				
Geno	toxicity in vivo	: Test Type: Mar	nmalian erythrocyte micronucleus test (in v				
		9 / 16					

according to the Hazardous Products Regulations



Losartan Formulation

/ersion 5.1	Revision Date: 09/26/2023	SDS Number: 19339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014
		cytogenetic a Species: Mo Application F Result: nega	use Route: Ingestion
Losa	rtan:		
Geno	toxicity in vitro	: Test Type: ir Result: nega	
			n vitro mammalian cell gene mutation test Chinese hamster ovary cells tive
		Test Type: A Result: nega	Ikaline elution assay tive
		Test Type: C Result: nega	Chromosomal aberration tive
Genc	toxicity in vivo	: Test Type: C Result: nega	Chromosomal aberration tive
Starc	:h:		
Genc	toxicity in vitro	: Test Type: B Result: nega	acterial reverse mutation assay (AMES) tive
	inogenicity		
	lassified based on ava	ailable information.	
	ponents:		
Spec	lose:	: Rat	
	cation Route	: Ingestion	
Expo	sure time	: 72 weeks	
Resu	lt	: negative	
Losa	rtan:		
Spec	ies	: Mouse	
	cation Route	: Oral	
Expo Dose	sure time	: 92 weeks : 200 mg/kg b	odv weight
Resu		: negative	
Spec	ies	: Rat	
Appli	cation Route	: Oral	
	sure time	: 105 weeks	
Dose Resu		: 270 mg/kg b	oay weight
Resu	lt	: negative	

according to the Hazardous Products Regulations



Losartan Formulation

Vers 5.1	sion	Revision Date: 09/26/2023		9S Number: 339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014
	May da	ductive toxicity amage the unborn child ause harm to breast-fec		ldren.	
	Comp	onents:			
	Cellul	ose:			
	Effects	s on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study
	Effects	on fetal development	:	Test Type: Fertility Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion
	Losart	an:			
	Effects	s on fertility	:	Result: female rep	ale : Oral 200 mg/kg body weight
	Effects	on fetal development	:	Developmental To Result: Embryoto	: Oral Maternal: NOAEL: 10 mg/kg body weight oxicity: NOAEL F1: 20 mg/kg body weight xic effects and adverse effects on the tected only at high maternally toxic doses,
	Reproo sessm	ductive toxicity - As- ent	:	Clear evidence of animal experimen	adverse effects on development, based on ts.
				Studies indicating period	a hazard to babies during the lactation

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

according to the Hazardous Products Regulations



Losartan Formulation

Version 5.1			
Co	omponents:		
Ro Ta	e sartan: outes of exposure rget Organs sessment		ardio-vascular system, Stomach, Kidney se damage to organs through prolonged or repeated
Re	peated dose toxicity		
Co	omponents:		
Sp NC Ap	ellulose: DAEL plication Route posure time	: Rat : >= 9,000 : Ingestion : 90 Days	
Lo	sartan:		
LĊ Ap Ex Nu	ecies DAEL plication Route posure time Imber of exposures rget Organs	: Rat : 15 mg/kg : Oral : 309 d : daily : Blood, Kid	dney, Cardio-vascular system, Stomach
NC Ap Ex	ecies DAEL plication Route posure time mptoms	: Dog : 5 mg/kg : Oral : 1 Months : Salivation	n, Vomiting
LĊ Ap Ex Nu	ecies DAEL plication Route posure time Imber of exposures mptoms	: Dog : 25 mg/kg : Oral : 53 Weeks : daily : Salivation	
Sp NC Ap Ex	arch: DAEL plication Route posure time ethod	: Rat : >= 2,000 : Skin conta : 28 Days : OECD Te	

Aspiration toxicity

Not classified based on available information.

according to the Hazardous Products Regulations



Losartan Formulation

Versio 5.1	on Revision Date: 09/26/2023		OS Number: 339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014							
<u>c</u>	Components:										
_	Losartan: No aspiration toxicity classification										
E	Experience with human exposure										
<u>c</u>	Components:										
L	_osartan:										
	Eye contact ngestion	:	Symptoms: Eye i Symptoms: hypo	rritation tension, tachycardia							
SECT	TION 12. ECOLOGICAL INF	ORM	IATION								
E	Ecotoxicity										
<u>c</u>	Components:										
C	Cellulose:										
T	Γoxicity to fish	:	Exposure time: 4	tipes (Japanese medaka)): > 100 mg/l 8 h on data from similar materials							
L	_osartan:										
٦	Foxicity to fish	:	LC50 (Oncorhynd Exposure time: 9 Method: FDA 4.1								
	Foxicity to daphnia and other aquatic invertebrates	r:	Exposure time: 4	nagna (Water flea)): 331 mg/l 8 h ēst Guideline 202							
	Foxicity to algae/aquatic blants	:	NOEC (Microcys Exposure time: 1 Method: FDA 4.0								
			NOEC (Selenasti Exposure time: 1 Method: FDA 4.0								
	Foxicity to fish (Chronic tox- city)	:	Exposure time: 3	les promelas (fathead minnow)): 10 mg/l 2 d ⁻ est Guideline 210							
a	Foxicity to daphnia and other aquatic invertebrates (Chron c toxicity)		Exposure time: 2	magna (Water flea)): 100 mg/l 1 d est Guideline 211							

according to the Hazardous Products Regulations



Losartan Formulation

ersion .1	Revision Date: 09/26/2023	SDS Number: 19339-00022	Date of last issue: 03/20/2023 Date of first issue: 10/07/2014
Pers	istence and degradal	oility	
<u>Com</u>	ponents:		
•••••	u lose: egradability	: Result: Read	ly biodegradable.
Losa	artan:		
Stab	ility in water	: Hydrolysis: <	10 %(5 d)
Bioa	ccumulative potentia	I	
<u>Com</u>	ponents:		
Parti	artan: tion coefficient: n- nol/water	: log Pow: 1.2	
Mob	ility in soil		
No d	ata available		
•	er adverse effects ata available		

Disposal methods

Waste from residues		Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG Not regulated as a dangerous good

according to the Hazardous Products Regulations



Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	19339-00022	Date of first issue: 10/07/2014

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safe- ty, Schedule 1, Part 1: Permissible exposure values for air- borne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWAEV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No

according to the Hazardous Products Regulations



Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	19339-00022	Date of first issue: 10/07/2014

1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
Revision Date Date format	:	09/26/2023 mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8